Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma (Nasdaq: PPCB) highlights preclinical and near‑term clinical plans for lead asset PRP, an investigational proenzyme therapy targeting metastatic solid tumors.

Rhea-AI Summary

Propanc Biopharma (Nasdaq: PPCB) highlights preclinical and near‑term clinical plans for lead asset PRP, an investigational proenzyme therapy targeting metastatic solid tumors. Key points: >85% tumor growth inhibition in pancreatic models, FDA Orphan Drug status for pancreatic cancer, a $100M funding facility, new patents, and a planned Phase 1b first‑in‑human trial in 2026 for 30–40 advanced solid tumor patients.

The company positions PRP as a multi‑targeted approach that may sensitize tumors, reduce fibrosis and resistance markers, and potentially lower toxicity versus standard therapies.

Positive

• >85% tumor growth inhibition reported in preclinical pancreatic models
• FDA Orphan Drug status granted for pancreatic cancer
• $100M funding facility available to support development
• Phase 1b first‑in‑human trial planned in 2026 for 30–40 patients

Negative

• No large human efficacy data yet; clinical benefit remains unproven
• Compassionate rectal study limited: survival from ~5.6 to 9 months in advanced cases
• Preclinical results may not translate to human efficacy without positive clinical trials

Argus Mar 3 session

-5.16% close to close Open Argus

Details

News Market Reaction – PPCB

On Mar 3, the day this news came out, PPCB closed 5.16% below the previous close.

Data tracked by StockTitan Argus for the Mar 3 session.

Market Context

On Mar 3, the day this news came out, the stock closed 5.2% below the previous close. A negative rea...

Analysis

On Mar 3, the day this news came out, the stock closed 5.2% below the previous close. A negative reaction despite encouraging preclinical data fits a pattern where PPCB often sold off on seemingly positive news, with 3 recent divergences. The stock traded at 0.1821, far below its 24 52‑week high and under the 200-day MA, reflecting prior dilution and going‑concern warnings. Investors may have focused on long timelines to monetization and execution risk around the planned Phase 1b trial despite >85% tumor inhibition data.

Key Figures

Tumor growth inhibition: >85% Pancreatic 5-year survival: 13% Overall cancer survival: 70% +5 more

Tumor growth inhibition

>85%

Preclinical pancreatic cancer models for PRP

Pancreatic 5-year survival

13%

Five-year survival rate for pancreatic cancer

Overall cancer survival

70%

Overall five-year cancer survival benchmark

Compassionate study survival

5.6 to 9 months

Small rectal PRP study in advanced cases

Phase 1b sample size

30–40 patients

Planned First-In-Human trial in 2026

2026 market size

$4.42B

Global pancreatic cancer treatment market value in 2026

2034 market projection

$14.43B

Projected pancreatic cancer treatment market by 2034

Funding facility

$100M

Fresh facility backing Phase 1b trial and development

Historical Context

5 past events · Latest: Feb 18

5 events

1. Feb 18

   Corporate update & results

   24h Move

   -4.5%

   Half-year results, asset summary, IP expansion and private placement facility details.

2. Feb 05

   PRP therapy spotlight

   24h Move

   +5.7%

   Highlighted PRP as game-changing therapy with strong preclinical data and large market.

3. Jan 27

   Provisional patent filing

   24h Move

   +6.5%

   Fourth provisional patent in two months strengthening PRP formulation IP and trial prep.

4. Jan 20

   New IP for Rec-PRP

   24h Move

   -4.7%

   Provisional patent on synthetic Rec-PRP production targeting metastatic cancer market.

5. Jan 15

   PRP preclinical overview

   24h Move

   -17.1%

   Detailed PRP preclinical efficacy, Orphan status, IPO funding and trial plans for 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

epithelial-mesenchymal transition (EMT), angiogenesis, tumor microenvironment, immunotherapies, +2 more

6 terms

epithelial-mesenchymal transition (EMT) medical

"blocks metastasis by suppressing epithelial-mesenchymal transition (EMT)"

Epithelial-mesenchymal transition (EMT) is a biological process where normally stationary, tightly linked cells change into a more mobile, flexible state, like office workers swapping uniforms to become delivery drivers. Investors should care because EMT drives disease spread and scarring and is a common target or risk factor in drug development and clinical trials; drugs that affect EMT can change a program’s chances of success, regulatory review, and market value.

angiogenesis medical

"disrupts the tumor microenvironment, curbs angiogenesis, and boosts chemosensitivity"

Angiogenesis is the biological process where the body builds new blood vessels, like laying new roads to deliver oxygen and nutrients to tissues. Investors care because many drugs aim to block or encourage this process to treat cancer, eye diseases, or chronic wounds; success or failure in controlling angiogenesis often determines a therapy’s effectiveness, regulatory approval, safety profile, and commercial potential.

tumor microenvironment medical

"disrupts the tumor microenvironment, curbs angiogenesis, and boosts chemosensitivity"

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

immunotherapies medical

"emerging options (immunotherapies, tumor-treating fields like Optune Pax)"

Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.

orphan drug status regulatory

"new patents, and FDA Orphan Drug status for pancreatic cancer"

An official label from health authorities for medicines that treat very rare diseases, given to encourage development by offering benefits such as reduced fees, tax breaks, and a period of exclusive sales. For investors it matters because these incentives lower development costs and can create a temporary monopoly-like advantage that boosts the drug’s potential revenue and valuation, much like a limited license that makes a risky project more commercially attractive.

phase 1b medical

"Phase 1b First-In-Human trial in 2026 (30–40 advanced solid tumor patients)"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market

MELBOURNE, Australia, March 03, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlights the potential of its lead asset, PRP, as a novel therapeutic approach to the treatment and prevention of metastatic cancer from solid tumors, especially more aggressively spreading, less differentiated tumors, which offer a poor patient prognosis. Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate stuck at just 13% and no real progress has been made in recent years. To put that into perspective, overall cancer survival is 70%.

Standard treatments like chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel), targeted therapies (e.g., KRAS inhibitors), and emerging options (immunotherapies, tumor-treating fields like Optune Pax) extend life modestly but often bring harsh side effects, resistance, and limited success against this aggressive, metastasis-prone disease.

Enter Propanc's PRP—a promising investigational proenzyme therapy (trypsinogen + chymotrypsinogen in a 1:6 ratio) delivered intravenously. Unlike cytotoxic drugs that kill dividing cells broadly, PRP targets cancer stem cells, blocks metastasis by suppressing epithelial-mesenchymal transition (EMT), disrupts the tumor microenvironment, curbs angiogenesis, and boosts chemosensitivity—potentially making standard treatments more effective with far less toxicity.

Preclinical data shines: >85% tumor growth inhibition in pancreatic models, reduced fibrosis and resistance markers, and a gentler profile (no major side effects in limited prior human use). A small compassionate study (rectal version) extended survival from ~5.6 to 9 months in advanced cases.

PRP vs. Current Treatment Options:

• Chemo: PRP could sensitize resistant tumors and cut doses/side effects.
• Targeted drugs: Broader attack on stem cells and spread, not just single mutations.
• Immunotherapy: May warm up “cold” pancreatic tumors by remodeling the microenvironment.
  

According to industry sources the global pancreatic cancer treatment market is valued at ~$4.42 billion in 2026 and projected to explode to $14.43 billion by 2034 (CAGR ~16%), fueled by rising cases and demand for better options.

Propanc is gearing up for a Phase 1b First-In-Human trial in 2026 (30–40 advanced solid tumor patients), backed by fresh funding ($100M facility), new patents, and FDA Orphan Drug status for pancreatic cancer.

“We are excited about PRP’s potential to transform cancer care by targeting the underlying mechanisms of metastasis with a mechanism that could offer meaningful advantages over existing therapies,” said James Nathanielsz, Propanc’s Chief Executive Officer. “PRP remains experimental—no large human efficacy data yet—but its multi-targeted, low-toxicity approach could redefine care for a disease desperate for breakthroughs,” Mr. Nathanielsz concludes.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

More information: www.propanc.com

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com

Investor Contact:
irteam@propanc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preclinical effect did PRP show in pancreatic cancer models for PPCB?

PRP demonstrated an over 85% tumor growth inhibition in preclinical pancreatic models. According to Propanc, studies also showed reduced fibrosis and lower resistance markers, suggesting potential to sensitize tumors and improve response to standard therapies.

What clinical trial does PPCB plan for PRP and when will it start?

Propanc plans a Phase 1b first‑in‑human trial in 2026 enrolling 30–40 advanced solid tumor patients. According to Propanc, the study aims to evaluate safety and early signals of activity in metastatic solid tumors.

Does PRP have any regulatory designations that affect PPCB’s development timeline?

PRP holds FDA Orphan Drug status for pancreatic cancer, which can streamline development incentives. According to Propanc, this designation may provide regulatory advantages such as fee reductions and market exclusivity upon approval.

How is Propanc financing PRP’s upcoming clinical program (PPCB)?

Propanc has access to a $100M funding facility intended to support development activities. According to Propanc, the facility underpins near‑term plans including the planned Phase 1b trial and related development costs.

What human evidence exists so far for PRP efficacy for PPCB?

Human evidence is limited: a small compassionate rectal study extended survival from ~5.6 to 9 months in advanced cases. According to Propanc, prior limited human use reported no major side effects, but large efficacy trials are pending.